Supplementary Figures – FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study
figure
posted on 2022-05-24, 10:13 authored by Taylor & FrancisTaylor & Francis, Alberto Servetto, Antonio Santaniello, Fabiana Napolitano, Francesca Foschini, Roberta Marciano, Priscilla Cascetta, Anna Rita Amato, Maria Rosaria Augurio, Lucia Maresca, Pietro De Placido, Sabino De Placido, Luigi Formisano, Roberto BiancoFigure 1: the efficacy of second-line treatment is not affected by responses in the first-line setting. Survival outcomes of the second-line regimens FFN and FOLFOX/CAPOX/FOLFIRI were not affected by the number of cycles of first-line NabGem
Figure 2: The mPFS2 and mOS2 of patients treated with second-line NabGem were 14.43 weeks and 21.28 weeks, respectively
